The high court said the plaintiffs’ “desire to make a drug less available to others” did not give them standing to challenge the FDA’s approval of mifepristone.
The high court said the plaintiffs’ “desire to make a drug less available to others” did not give them standing to challenge the FDA’s approval of mifepristone.